December 1, 2010Advances in Pulmonary HypertensionOpen Access

Health-related Quality of Life in Pulmonary Arterial Hypertension

View Full Paper

Ask AI

Bookmark

Population

Patients with pulmonary arterial hypertension (PAH) across 23 reviewed studies.

Design

Systematic_review

Follow-up

usually 12 to 16 weeks

Authors

AGAnn Gihl

Discussion

Member takes

Implication

HRQoL tools in PAH need disease-specific validation; leaves open optimal therapy selection pending longer trials.

Structured PICO

Population

Patients with pulmonary arterial hypertension (PAH) across 23 reviewed studies.

Intervention

Various interventions including pharmaceutical therapies (epoprostenol, iloprost, treprostinil, sildenafil, bosentan, ambrisentan, sitaxsentan), exercise training, and nursing interventions.

Outcome

Health-related quality of life (HRQoL)patient reported

This review highlights that while PAH severely impacts HRQoL and some therapies offer benefits, the field lacks robust, long-term data using disease-specific measurement tools like CAMPHOR.

Limitations

Small sample sizes
Differences in PAH etiology and comorbidities
Use of non-disease-specific HRQoL tools
Short study durations (usually 12-16 weeks)

Cite This Study

Ann Gihl (2010) studied this question.

synapsesocial.com/papers/6a813b33ba5888e95f4d7fd8 https://doi.org/10.21693/1933-088x-8.4.215

View Full Paper

Ask AI

Bookmark

December 1, 2010Advances in Pulmonary HypertensionOpen Access

Health-related Quality of Life in Pulmonary Arterial Hypertension

View Full Paper

Ask AI

Bookmark

Population

Patients with pulmonary arterial hypertension (PAH) across 23 reviewed studies.

Design

Systematic_review

Follow-up

usually 12 to 16 weeks

Authors

AGAnn Gihl

Discussion

Member takes

Implication

HRQoL tools in PAH need disease-specific validation; leaves open optimal therapy selection pending longer trials.

Structured PICO

Population

Patients with pulmonary arterial hypertension (PAH) across 23 reviewed studies.

Intervention

Various interventions including pharmaceutical therapies (epoprostenol, iloprost, treprostinil, sildenafil, bosentan, ambrisentan, sitaxsentan), exercise training, and nursing interventions.

Outcome

Health-related quality of life (HRQoL)patient reported

This review highlights that while PAH severely impacts HRQoL and some therapies offer benefits, the field lacks robust, long-term data using disease-specific measurement tools like CAMPHOR.

Limitations

Small sample sizes
Differences in PAH etiology and comorbidities
Use of non-disease-specific HRQoL tools
Short study durations (usually 12-16 weeks)

Cite This Study

Ann Gihl (2010) studied this question.

synapsesocial.com/papers/6a813b33ba5888e95f4d7fd8 https://doi.org/10.21693/1933-088x-8.4.215

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark